A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women Who Have Sex With Men

Trial Profile

A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women Who Have Sex With Men

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 05 Oct 2017

At a glance

  • Drugs Cabotegravir (Primary) ; Emtricitabine/tenofovir disoproxil fumarate
  • Indications HIV infections
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Most Recent Events

    • 31 May 2017 Planned primary completion date changed from 1 Jun 2020 to 30 Sep 2021.
    • 14 Dec 2016 Status changed from not yet recruiting to recruiting.
    • 29 Mar 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top